Sign in

You're signed outSign in or to get full access.

EP

ENANTA PHARMACEUTICALS INC (ENTA)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 FY25 revenue was $17.0M (all royalties from AbbVie’s MAVYRET/MAVIRET), down vs $18.0M YoY and up vs $14.6M in Q4, with net loss improving to $22.3M ($1.05) from $33.4M ($1.58) YoY as R&D and G&A continued to decline .
  • Operating loss improved to $23.5M vs $34.9M YoY and $29.9M in Q4; interest expense fell to $2.0M as OMERS royalty-debt amortization continued, while interest income declined on lower balances .
  • Liquidity: cash and short-term marketable securities were $216.7M at 12/31/24; management extended runway guidance to fiscal 2028 from fiscal 2027 previously, aided by disciplined OpEx and capital-efficient RSV planning .
  • Pipeline catalysts: Phase 2b RSVHR in high‑risk adults targeting topline in 3Q25; positive pediatric RSV zelicapavir and EDP‑323 challenge data support potential first‑/best‑in‑disease positioning; management is exploring partnerships for RSV .
  • No earnings call transcript was available this quarter; management commentary came via press release; S&P Global consensus estimates were unavailable at time of analysis due to access limits (cannot assess beat/miss).

What Went Well and What Went Wrong

  • What Went Well

    • Sequential revenue uptick amid stabilizing royalties; total revenue $17.0M vs $14.6M in Q4 .
    • OpEx discipline: R&D fell to $27.7M (timing of RSV trials and lower COVID-19 costs); G&A fell to $12.8M (lower litigation spend), improving operating loss YoY .
    • Pipeline momentum and optionality: positive pediatric zelicapavir antiviral effect and strong EDP‑323 challenge data; RSVHR adult study on track for topline in 3Q25; active exploration of RSV partnerships to extend cash runway .

  • What Went Wrong

    • YoY royalty headwind persisted as AbbVie’s MAVYRET/MAVIRET sales decline reduced revenue vs $18.0M YoY .
    • Interest income decreased to $2.8M on lower cash/investment balances; total liquidity declined to $216.7M from $248.2M in Q4 .
    • Estimates context not assessable: S&P Global consensus data unavailable, limiting beat/miss determination (see Estimates Context).

Financial Results

MetricQ1 FY24 (Dec 31, 2023)Q3 FY24 (Jun 30, 2024)Q4 FY24 (Sep 30, 2024)Q1 FY25 (Dec 31, 2024)
Revenue ($USD Millions)$18.0 $18.0 $14.6 $17.0
Loss from Operations ($USD Millions)$(34.9) $(24.2) $(29.9) $(23.5)
Net Loss ($USD Millions)$(33.4) $(22.7) $(28.8) $(22.3)
Diluted EPS ($)$(1.58) $(1.07) $(1.36) $(1.05)
R&D Expense ($USD Millions)$36.4 $28.7 $30.8 $27.7
G&A Expense ($USD Millions)$16.5 $13.4 $13.7 $12.8
Interest Expense ($USD Millions)$3.4 $2.4 $2.6 $2.0
Interest & Investment Income, net ($USD Millions)$4.3 $3.5 $3.2 $2.8
  • Cash and Short-Term Marketable Securities:
    • Q3 FY24: $272.6M total cash, cash equivalents and marketable securities
    • Q4 FY24: $248.2M
    • Q1 FY25: $216.7M

Segment/Revenue Composition (Q1 FY25):

  • Royalty revenue (AbbVie MAVYRET/MAVIRET): $17.0M; no product sales; revenue fully comprised of royalties .

Key Royalty/Financing Mechanics:

  • 54.5% of HCV royalties are paid to OMERS through June 30, 2032 (capped at 1.42x the $200M upfront); Enanta records 100% revenue and amortizes the royalty‑sale liability; interest expense was $2.0M in Q1 .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash RunwayCorporate liquiditySufficient through fiscal 2027 Sufficient into fiscal 2028 Raised/extended
RSVHR (zelicapavir) – Adult High‑Risk Phase 2bDevelopment timelineTargeting enrollment completion in current NH season Completion in current NH season; topline data in 3Q25 Timing clarified
STAT6 inhibitorsDevelopment milestoneLead optimization activities in 2025 Select STAT6 lead candidate in 2H 2025 Timing specified
KIT inhibitor (EPS‑1421)IND/scale‑upScale‑up & IND enabling studies planned in 2025 IND enabling studies ongoing in 2025 Maintained/progress update
Pediatric RSV (zelicapavir)Topline readoutTopline data expected Dec 2024 Positive pediatric antiviral effect announced Dec 2024; presenting at RSV 2025 Delivered/result dissemination

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 FY24)Previous Mentions (Q4 FY24)Current Period (Q1 FY25)Trend
RSV portfolio momentum (zelicapavir, EDP‑323)Completed pediatrics enrollment; EDP‑323 Phase 2a completed; topline near‑term EDP‑323 positive topline; pediatrics topline Dec 2024; RSVHR enrollment progressing Pediatric antiviral effect announced; RSVHR topline 3Q25; RSV data to be presented at RSV 2025 Strengthening evidence; clear adult readout timing
Partnership strategy for RSVNot emphasizedNot emphasizedExploring partnership opportunities to advance RSV program New emphasis on BD to fund next phases
OpEx disciplineR&D down on reduced COVID efforts; legal spend higher R&D down YoY; G&A up YoY due to legal fees R&D and G&A both down YoY; legal spend easing Continued cost control
Liquidity/runway$272.6M total liquidity; runway through Q3 FY27 $248.2M; runway through FY27 $216.7M; runway into FY28 Runway extended despite lower balances
Legal/regulatory (Pfizer ‘953)——Appeal filed Feb 3, 2025 to Federal Circuit on Pfizer patent case Active appellate process

Management Commentary

  • “2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across our pipeline... With both zelicapavir and EDP‑323, we have the leading portfolio of RSV candidates in clinical development today... we will be exploring potential partnership opportunities... thereby extending our cash runway into fiscal 2028.” — Jay R. Luly, Ph.D., President & CEO .
  • “We are rapidly advancing and expanding our immunology portfolio targeting Type 2 immune diseases... We expect to select a lead development candidate for STAT6 in the second half of this year.” — Jay R. Luly, Ph.D. .

Q&A Highlights

  • No Q1 FY25 earnings call transcript was available; recent practice included providing updates via press releases, and no call was held for the Q4 FY24 update .

Estimates Context

  • Wall Street consensus (S&P Global) for Q1 FY25 EPS and revenue was unavailable at time of analysis due to access limits in the SPGI feed; therefore, we cannot determine beat/miss versus consensus at this time.

Key Takeaways for Investors

  • Revenue base remains royalty‑driven and modestly variable with AbbVie HCV trends; sequential improvement in Q1 provides near‑term stability while pipeline catalysts approach .
  • Cost discipline (lower R&D and G&A) improved operating and net losses YoY; continued focus on capital‑efficient trial execution .
  • RSV program has two validated mechanisms (N‑ and L‑protein inhibitors) with positive signals across pediatrics and human challenge, creating “first‑/best‑in‑disease” optionality ahead of RSVHR adult topline in 3Q25—key trading catalyst window .
  • Active exploration of partnerships could de‑risk funding for late‑stage RSV and extend runway; BD outcomes are a medium‑term stock driver .
  • Liquidity runway extended to fiscal 2028, giving the company time to prosecute RSV and advance immunology (KIT, STAT6) through key inflections .
  • Watch for: RSVHR enrollment completion and 3Q25 topline, RSV 2025 symposium data flow, selection of STAT6 development candidate in 2H25, and updates on Pfizer ‘953 appeal .

References: 8‑K and press releases with financial tables and management commentary .